Articles tagged with Cancer Medication
Researchers used Cryo-EM to capture images of molecular machinery called RNA Polymerase III in unprecedented detail, revealing five key stages in which the complex reshapes itself to successfully transcribe the DNA code. This discovery could open up new approaches to cancer treatment by targeting the complex's activity.
A randomized controlled trial found that systematic bright light exposure improved sleep efficiency and self-reported sleep quality in fatigued cancer survivors. The intervention showed significant effects compared to dim light exposure.
The NHS bowel scope screening programme saw a significant increase in uptake when patients were sent additional reminders addressing common concerns, highlighting the importance of patient information and support., Bowel cancer is the 4th most common cancer in the UK, with over half of cases diagnosed at a late stage.
RAS molecules act in pairs, known as dimers, to cause cancer and transmit signals that tell a cell to grow and divide. The study provides a foundation for further studies on RAS biology and could potentially pave the way to develop new cancer drugs.
Researchers found that activating REV-ERB proteins can starve cancer cells by blocking nutrient production, while normal cells are not affected. The discovery sheds light on a new uncharacterized way to treat cancer with limited toxicity.
A recent study by Queen Mary University of London found that protein markers are a more accurate predictor of patient responses to midostaurin, a new leukemia treatment. This breakthrough could lead to double the number of patients being treated and improve outcomes for those with acute myeloid leukemia.
Researchers have identified MED1 as a key player in HER2-driven breast cancer development and spread. The study found that mutating MED1 disrupted its interaction with the estrogen receptor, significantly delaying tumor growth and cancer stem-like cell formation.
A study found that new treatments and screening methods have reduced breast cancer deaths by 49% since 2012, compared to 37% in 2000. The reduction is largely due to advances in treatment, with screening contributing 31-48% depending on the molecular subtype.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
The UC Santa Cruz Genomics Institute's Treehouse Childhood Cancer Initiative has received a $500,000 grant to conduct a 24-month registry study evaluating the effectiveness of comparative RNA-seq analysis in pediatric cancer treatment. The project aims to assess the impact on clinical decision-making and patient outcomes.
Manning's research focuses on the role of retinoblastoma protein in regulating chromosome segregation. Her work aims to understand how defects in this process contribute to genetic variability and chemotherapy resistance in tumors. The study may lead to new targets for anti-cancer medications.
Researchers at Tel Aviv University discovered an inverse correlation between a known oncogene and tumor suppressant, leading to extended survival rates in pancreatic cancer patients. A novel nanoparticle delivery system selectively targets cancer cells, rendering them dormant or eradicating the tumor altogether.
Researchers have discovered that experimental diabetes drugs can make cancer cells more vulnerable to traditional chemotherapy agents. The combination of carboplatin and one of the experimental compounds, SR1664, sensitized lung tumor cells and triple-negative breast cancer cells in laboratory models, leading to reduced tumor growth.
The new guidelines provide strategies for including patients with brain metastases in clinical trials, addressing the lack of data on drug effects in the brain. The approach includes three specific strategies based on initial understanding of a drug's possible activity in the brain.
A new study from the University of Pennsylvania School of Medicine found that 18% of multiple myeloma patients experiencing cardiovascular adverse events (CVAE) such as hypertension, heart failure, or arrhythmia. Higher doses of carfilzomib are associated with higher rates of CVAE, and the drug is linked to an elevated risk of CVAE com...
A University of Hawaii Cancer Center researcher has identified a mechanism that drives cancer cells to move during metastasis. The study defines a signaling hub required for cancer cell movement, which may provide new therapeutic opportunities for brain tumors and other cancers.
Researchers developed a mathematical model that simulates tumor growth and predicts response to cancer drugs. The model uses parameters of tumor growth to forecast treatment effectiveness, potentially leading to new strategies for predicting tumor response.
A new USC study reveals that tumor growth properties can influence response to cancer drugs. Researchers found certain parameters of tumor growth can forecast the effectiveness of anti-angiogenic treatment, allowing for more accurate predictions. This breakthrough has the potential to improve cancer therapy outcomes.
A new class of medicines called HIF-2a inhibitors, including PT2385, have shown promise in treating metastatic kidney cancer. The drug blocked tumor growth for at least 4 months in 40% of patients and stopped cancer growth for over a year in 25% of patients with minimal side effects.
Researchers at Harvard Medical School have discovered a novel therapeutic strategy to treat drug-resistant thyroid cancers by combining vemurafenib with palbociclib, a CDK4/6 inhibitor. The treatment was shown to induce stronger cell death than when used alone, offering new hope for patients with papillary thyroid carcinoma.
Researchers developed an algorithm using smartphone data to detect worsening symptoms in cancer patients, allowing for early intervention and improved quality of life. The study enrolled 14 patients undergoing chemotherapy treatment, showing 88% accuracy in identifying high-symptom days.
A study found that high out-of-pocket costs for oral cancer medications lead to prescription abandonment, even among those with insurance. Patients faced with costs over $2,000 were more likely to abandon their prescriptions, highlighting the need for strategies to improve patient access.
A new study led by Johns Hopkins Medicine researchers found that tumors with high mutational burden are more likely to respond to checkpoint inhibitors, a class of cancer immunotherapy drugs. The study suggests that precision medicine could be used to guide clinical trials and improve treatment outcomes for specific patient populations.
A recent study published in Oncotarget found that cancer drug affordability is correlated with wealth, with the US having the highest average monthly price per patented drug. This has led to a financial burden on both society and patients, with individuals diagnosed with cancer being 2.7 times more likely to declare bankruptcy.
Scientists have successfully packaged a cancer drug into sperm cells, which were then guided to cervical cancer cells using magnetic forces. The loaded sperm killed over 80% of the cancerous tumor with minimal payload loss.
Cisplatin, a common cancer drug, causes permanent hearing loss in 40-80% of adult patients and at least half of children. Researchers found that the inner ear builds up the drug, leading to damage. Targeting the stria vascularis region could prevent cisplatin-induced hearing loss.
Four biomedical researchers from Aligarh Muslim University, National Institute of Immunology India, and University of Torino presented groundbreaking studies on kidney cancer treatment, chemoresistance, and asbestos-related tumors at FCS 2017. Oncotarget's travel grants enabled their participation in the conference.
Researchers at the University of Illinois found that cross-system signaling activity between growth factors can direct blood vessel growth and influence cancer progression, stroke recovery, and other disorders. This discovery offers a new pathway to developing effective therapies by promoting or inhibiting this signal.
A new study found that factors such as persistent symptoms, comorbidities, leisure-time physical activity, and financial challenges affect health-related quality of life in older adults with cancer. The research highlights the importance of comprehensive care that addresses these factors to improve outcomes for this vulnerable population.
Researchers found that mature cells can revert to a stem cell-like state, carrying accumulated mutations that predispose them to developing into precancerous lesions. This new understanding could lead to the development of treatments targeting mature cells, potentially preventing cancer recurrence.
A KAIST research team developed technology to identify the optimal drug target for cancer cells based on molecular network dynamics. This approach uses systems biology to analyze genetic mutations and predict drug response, which could lead to more effective treatment strategies.
Research at Columbia University Irving Medical Center found that cancer patients with more versions of human leukocyte antigen (HLA) genes respond better to checkpoint inhibitors. The study also showed that certain HLA patterns affect survival and may be relevant for understanding side effects observed with immunotherapy.
A team of researchers at the University of Michigan Comprehensive Cancer Center identified a novel gene called THOR that plays a role in cancer development. Knocking out THOR was found to halt tumor growth, while overexpressing it led to increased cell proliferation.
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of bet hedging. Genetic variations in cancer lead to differences in drug response, making combination therapy more effective by boosting the likelihood that a patient will benefit from at least one drug.
Researchers at Duke University Medical Center are using drug discovery methods that have fueled cancer breakthroughs to identify alternatives to antibiotics for Lyme disease and other tick-borne illnesses. By targeting vulnerable areas of disease-causing bacteria, they aim to develop new therapies that spare the normal gut microbiome.
Researchers present promising results from clinical trials suggesting patients with blood disorders and several types of cancer will soon have expanded treatment options. The studies show significant breakthroughs in reducing risks during rare blood disorders, such as thrombotic thrombocytopenic purpura, and improving treatment for mul...
A new study reveals that mutations in 'Ras' genes, which drive 25% of human cancers, can also suppress the immune system around tumors by increasing PD-L1 levels. This understanding will help offer patients more precise and effective treatments.
A recent study by Georgia State University's School of Public Health found that trust in e-cigarette safety differs depending on an individual's worldview and the source of the message. People with hierarchical and individualistic worldviews tend to be less trusting of health experts and more trusting of tobacco companies.
A multi-national phase Ib study has demonstrated a complete response in up to 50 percent of patients with relapsed or refractory acute myeloid leukemia (AML) treated with venetoclax and idasanutlin. The combination therapy shows promise as an effective treatment option for patients with limited treatment options.
A Phase 2 study of axi-cel, a CD19-targeting CAR T cell therapy, reported remarkable improvement in outcomes for patients with relapsed or refractory large B-cell lymphoma. The study showed that 42% of patients remained in remission at 15 months, with complete responses in 54% and measurable responses in 82%.
Novel targeted cancer therapies have been shown to improve progression-free survival, response rate, and quality of life for patients with cutaneous T-cell lymphoma. Mogamulizumab has demonstrated significant clinical activity in clearing malignant T-cells in the blood and lymph nodes.
A large-scale study reveals acupuncture to be effective in alleviating joint pain experienced by breast cancer patients undergoing hormone therapy. The treatment resulted in significant pain relief for up to 24 weeks, providing a promising alternative to opioids and other medications.
A recent study published in Annals of Behavioral Medicine found that higher Fitbit step counts during inpatient recovery were associated with lower risk of readmission after metastatic peritoneal cancer surgery. The researchers monitored patients using Fitbits and found that more activity was linked to better patient outcomes.
A study published in PLOS ONE found that metformin can prevent the development of multidrug-resistant breast cancer and reverse it after its onset. The research suggests that metformin has potential as a treatment option for aggressive breast cancer, warranting further investigation.
A study found that a cancer medication can improve symptoms of Huntington's disease in mice, including increased mobility and longer lifespan. The drug targets mitochondrial health and protein removal, also relevant to other neurodegenerative disorders.
Researchers at Queen's University have successfully used magnetic fields to direct magnetotactic bacteria against strong currents, opening up the potential for these microbes to deliver pharmaceuticals directly to tumors. The team aims to bind therapeutic drugs to the bacterial bodies and release them once they reach their destination.
A new treatment approach for ovarian cancer has shown promising results in a mouse model. Combining drugs that reactivate dormant genes with those that activate the immune system led to greater tumor reduction and longer survival rates compared to single-drug treatments.
A recent study published in Annals of Internal Medicine found that cocaine overdose deaths disproportionately impact the non-Hispanic black population, with rates comparable to those for heroin and prescription opioid-related deaths. The research highlights the need for targeted prevention efforts among this demographic.
A new treatment combines traditional chemotherapy with a relatively new cancer drug that targets chemo-resistant tumor cells, loaded into tiny nanoparticles. The treatment shows promise for improving survival rates for endometrial cancer patients and could be used to treat other cancers as well.
The Ontario Institute for Cancer Research has launched the Cancer Therapeutics Innovation Pipeline to translate new discoveries into cancer therapies. The pipeline selected 10 projects for funding and will provide guidance from industry and academia experts.
Researchers have identified a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide. The strategy uses a gene profile alone to predict which tumors are susceptible to αvβ3 blockade, offering a new therapeutic target for precision medicine in brain cancer treatment. Thi...
Kinase inhibitors show promise in treating various types of blood and lung cancers by blocking overactive enzymes that control cell growth. Researchers identified new target structures for drugs, including the kinase MELK, which is linked to poor prognosis in lung cancer.
Researchers at Johns Hopkins Kimmel Cancer Center have identified a novel drug combination that can prime nonsmall cell lung cancers to respond better to immunotherapy. The treatment, which combines a demethylating drug with an HDAC inhibitor, triggered a chemical cascade that increased the attraction of immune cells to fight tumors an...
The American Society for Cell Biology (ASCB) has announced 67 new Fellows, recognizing their significant and sustained impact on the discipline of cell biology. The honor is bestowed by peers and acknowledges not only outstanding scientific contributions but also service to ASCB and its missions.
Researchers at Carnegie Mellon University developed a new method to improve chemotherapy nanodrug delivery by using an FDA-approved nutrition source. This approach reduces toxic side-effects and increases the amount of drugs reaching tumor cells.
Researchers at Imperial College London conducted a clinical trial using immunotherapy drug pembrolizumab on four patients with multi-drug resistant GTD. The study found that three out of four patients went into remission, with no signs of cancer recurrence for between five months to over two years.
Researchers at UC San Diego School of Medicine will conduct clinical trials to test the PI3Ky inhibitor IPI-549 in combination with checkpoint inhibitors for head and neck cancers, aiming to boost immunotherapy effectiveness.
University of Illinois researchers designed nanoparticles that specifically bind to breast cancer stem cells, delivering a drug that turns off key gene pathways. The treatment significantly decreased cancer cell growth and made cancer stem cells less able to cause recurrence.
PAC-1, a cancer drug that targets procaspase-3, has been approved for use in a phase Ib trial of patients with anaplastic astrocytoma and glioblastoma multiforme. The drug has shown promise in pet dogs with brain cancers and is being tested in combination with temozolomide.
Researchers discovered that these antimalarial drugs make tumour cells more sensitive to cancer treatment, suggesting potential benefits for certain cancer patients. The findings have sparked excitement among scientists, who are now eagerly awaiting the results of ongoing clinical studies.